Taken together, our MOC2-CIITA vaccination results demonstrate that for OSCC tumors the CIITA-mediated MHC-II expression is instrumental to trigger the initial phase of the adaptive immune response, particularly the key triggering of tumor specific CD4+ T cells that in turn activate and allow the functional maturation of CD8+ tumor-specific CTL. The gene discussed is CD4; the disease is neoplasm.